Unknown Lungs & Breathing NIHR-supported project Digestion, Kidneys & Other Organs

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis

Funder NIHR (part of DHSC)
Recipient organisation NIHR Wellcome Trust Manchester Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Feb 2025 — Ongoing

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Peter Arkwright (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (M17-380 - Upa to Dupil in Paed Atopic Dermatitis)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
A phase 3, randomised, placebo controlled, double blind study to evaulate upadacitinib in combination with topical corticosteroids in adolescent and adult subjects with moderate to severe atopic dermatitis [M18-891]
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >= 6 to <18 Years of Age with Atopic Dermatitis
A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.